MIST’s CARDAMYST launch gains momentum on adoption and coverage
CARDAMYST’s launch is seeing strong adoption by electrophysiologists and positive payer coverage, with efforts shifting to cardiologist awareness. Revenue per script is expected to rise as coverage expands and free drug programs end.